Journal of Rheumatic Diseases最新文献_第3页

Joint accumulation and sustained remission in early rheumatoid arthritis. 早期类风湿关节炎的关节积累和持续缓解。

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2026-02-26 DOI: 10.4078/jrd.2026.0014

Hyoun-Ah Kim

引用次数: 0

Anti-neutrophil cytoplasmic antibody-associated vasculitis following allogenic bone marrow transplantation and chronic graft-versus-host disease: a rare case. 同种异体骨髓移植和慢性移植物抗宿主病后的抗中性粒细胞细胞质抗体相关血管炎：罕见病例。

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2025-07-02 DOI: 10.4078/jrd.2025.0030

Maria Rita Dias, Mariana Dias Pais, Catarina Pereira Eusébio, Sara Vilela, Gonçalo Calheiros Cruz, Ana Messias, Fernando Godinho Pereira, Filipa Fonte Rodrigues, Rita Theias Manso, Cristina Santos

{"title":"Anti-neutrophil cytoplasmic antibody-associated vasculitis following allogenic bone marrow transplantation and chronic graft-versus-host disease: a rare case.","authors":"Maria Rita Dias, Mariana Dias Pais, Catarina Pereira Eusébio, Sara Vilela, Gonçalo Calheiros Cruz, Ana Messias, Fernando Godinho Pereira, Filipa Fonte Rodrigues, Rita Theias Manso, Cristina Santos","doi":"10.4078/jrd.2025.0030","DOIUrl":"10.4078/jrd.2025.0030","url":null,"abstract":"Anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) are rare autoimmune disorders typically involving the lungs and kidneys. A few case reports have described an association with hematopoietic stem cell transplant (HSCT). We present a case of myeloperoxidase-positive AAV with predominant renal involvement in a 49-year-old male with a history of acute myeloid leukemia treated with allogenic HSCT and complicated by chronic graft-versus-host disease (GVHD). He presented with rapidly progressive glomerulonephritis, and kidney biopsy revealed pauci-immune necrotizing crescentic glomerulonephritis. Treatment with methylprednisolone pulses followed by oral prednisolone, rituximab, and plasmapheresis led to improved kidney function and a tailored rituximab maintenance regimen was followed. However, a renal-limited relapse occurred at 15 months, requiring repeat induction therapy. Dialysis was avoided, but renal function only partially recovered. This case suggests that AAV can develop after HSCT and GVHD and highlights the importance of long-term follow-up and further research into underlying mechanisms.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 2","pages":"122-126"},"PeriodicalIF":3.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of active tuberculosis in Korean patients with rheumatoid arthritis: a comparison between tumor necrosis factor inhibitors and tofacitinib. 韩国类风湿关节炎患者活动性结核的发病率：肿瘤坏死因子抑制剂与托法替尼的比较

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2025-11-27 DOI: 10.4078/jrd.2025.0091

Jeong-Yeon Kim, Seung-Hun You, Yoon-Kyoung Sung, Sun-Young Jung, Soo-Kyung Cho

{"title":"Incidence of active tuberculosis in Korean patients with rheumatoid arthritis: a comparison between tumor necrosis factor inhibitors and tofacitinib.","authors":"Jeong-Yeon Kim, Seung-Hun You, Yoon-Kyoung Sung, Sun-Young Jung, Soo-Kyung Cho","doi":"10.4078/jrd.2025.0091","DOIUrl":"10.4078/jrd.2025.0091","url":null,"abstract":"Objective: This study aims to compare the incidence of active tuberculosis (TB) among Korean patients with rheumatoid arthritis (RA) initiating treatment with tumor necrosis factor inhibitors (TNFi) or tofacitinib.Methods: Using the Korean National Health Insurance database, we conducted a nationwide, retrospective cohort study of RA patients who started TNFi or tofacitinib therapy between 2015 and 2018. We calculated the incidence rates of active TB based on the treatment type and results from latent tuberculosis infection (LTBI) screening tests. A multivariable Cox proportional hazards model was employed to evaluate the risk of active TB in RA patients beginning TNFi or tofacitinib treatment.Results: Among 3,382 RA patients (596 on tofacitinib and 2,786 on TNFi), LTBI screening was predominantly conducted using the IGRA (interferon-gamma release assays) test. Of these patients, 624 (18.5%) with a positive LTBI test received prophylactic treatment. No cases of active TB occurred in tofacitinib users, while 32 cases were observed in TNFi users. The adjusted hazard ratio for active TB in LTBI-positive patients was 5.47 (95% confidence interval 2.74 to 10.92) compared to LTBI-negative patients. In subgroup analyses, TB incidence was significantly higher among individuals aged over 65 years.Conclusion: Despite LTBI treatment, active TB remains prevalent among RA patients on TNFi therapy and in those with positive LTBI tests.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 2","pages":"95-101"},"PeriodicalIF":3.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea. 生物疾病改善抗风湿药物在青少年特发性关节炎中的治疗模式：韩国一项基于人群的研究。

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2025-09-17 DOI: 10.4078/jrd.2025.0101

Jong Gyun Ahn, Min-Taek Lee, Daye Lee, Eun Jeong Min, Dae Chul Jeong

{"title":"Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea.","authors":"Jong Gyun Ahn, Min-Taek Lee, Daye Lee, Eun Jeong Min, Dae Chul Jeong","doi":"10.4078/jrd.2025.0101","DOIUrl":"10.4078/jrd.2025.0101","url":null,"abstract":"Objective: Juvenile idiopathic arthritis (JIA) is the most common chronic arthritis in children, with an unknown cause and prolonged disease course. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have improved outcomes in severe or refractory cases, but challenges remain due to disease heterogeneity and long-term management needs. Understanding treatment patterns of novel therapies is essential for optimizing care. This study aimed to investigate bDMARD treatment patterns in JIA patients using a real-world database.Methods: A retrospective analysis was conducted using Health Insurance Review and Assessment (HIRA) national claims data from 2007 to 2019. JIA patients were classified into bDMARDs and non-bDMARDs groups, with treatment patterns compared.Results: Among 1,728 JIA patients, 31.3% (n=541) received bDMARDs, with 15.5% (n=84) discontinuing treatment. The median time from diagnosis to first bDMARD was 36.7 (9.7~58.1) months, with a median treatment duration of 28.1 (11.5~54.4) months and follow-up of 24.3 (7.7~43.7) months post-discontinuation. In the non-bDMARDs group (68.7%, n=1,187), 68.7% (n=815) used conventional synthetic DMARDs (csDMARDs), with a 46.6% (n=380) discontinuation rate. Methotrexate, sulfasalazine, and hydroxychloroquine were the most prescribed csDMARDs. Etanercept (69.7%) was the most common first bDMARD, followed by adalimumab (19.0%) and tocilizumab (7.6%), with 14.8% switching to a second biologic. Discontinuation rates of csDMARDs were higher in the non-bDMARDs group (p<0.001).Conclusion: This is the first comprehensive study profiling the treatment patterns of Korean patients with JIA using population-based claims data. The findings enhance understanding of real-world treatment trends, aiding clinical decision-making.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 2","pages":"111-121"},"PeriodicalIF":3.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving landscape of imaging-based evaluation in systemic autoimmune rheumatic disease-associated interstitial lung disease: from visual assessment to quantitative artificial intelligence-assisted evaluation. 系统性自身免疫性风湿性疾病相关间质性肺病影像学评估的发展前景：从视觉评估到定量人工智能辅助评估

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2026-02-20 DOI: 10.4078/jrd.2025.0161

Sung Hae Chang, Gregory C McDermott, Yeon-Ah Lee, Eun Ha Kang, Yong-Beom Park, Jung-Yoon Choe, Eun Young Lee, Jeffrey A Sparks

{"title":"Evolving landscape of imaging-based evaluation in systemic autoimmune rheumatic disease-associated interstitial lung disease: from visual assessment to quantitative artificial intelligence-assisted evaluation.","authors":"Sung Hae Chang, Gregory C McDermott, Yeon-Ah Lee, Eun Ha Kang, Yong-Beom Park, Jung-Yoon Choe, Eun Young Lee, Jeffrey A Sparks","doi":"10.4078/jrd.2025.0161","DOIUrl":"10.4078/jrd.2025.0161","url":null,"abstract":"Interstitial lung disease (ILD) is a major driver of morbidity and mortality across systemic autoimmune rheumatic diseases (SARDs), with systemic sclerosis-associated ILD (SSc-ILD) providing the most extensive evidence base. In this context, progressive pulmonary fibrosis has emerged as a central framework, as it is associated with increased mortality and facilitates the identification of candidates for antifibrotic therapy. Nevertheless, operational thresholds for chest high-resolution computed tomography (HRCT)-defined progression remain ill defined: current guidelines rely on visual HRCT interpretation and lack standardized, reproducible assessment protocols. Because the magnitude and topography of disease evolution can guide therapeutic decisions, quantitative evaluation of imaging features is pivotal. In this review, we delineate the evolution of imaging assessment from qualitative reads to quantitative phenotyping. We organize traditional densitometric and textural metrics (e.g., percentage high-attenuation areas, quantitative lung fibrosis, CALIPER [Computer-Aided Lung Informatics for Pathology Evaluation and Ratings]) alongside hybrid/data-driven approaches (e.g., data-driven textural analysis, quantitative interstitial abnormality) and recent deep-learning tools (e.g., SOFIA [Systemic Objective Fibrotic Imaging Analysis Algorithm], eLung, Qureight, SATORI [Segmentation and Annotation Tool for Radiomics and Deep Learning], AirQuant). Given the rapid pace of innovation in artificial-intelligence-based quantitative CT, we present a curated set of analytic approaches and offer a concise framework for understanding technological progress and evaluating its relevance to SARD-ILD applications.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 2","pages":"73-93"},"PeriodicalIF":3.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13086278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of hematological changes in patients with rheumatoid arthritis treated with different Janus kinase inhibitors: a real-world study. 不同Janus激酶抑制剂治疗的类风湿关节炎患者血液学变化的比较分析：一项真实世界的研究。

IF 3.8

Journal of Rheumatic Diseases Pub Date : 2026-04-01 Epub Date: 2025-09-26 DOI: 10.4078/jrd.2025.0081

Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong

{"title":"Comparative analysis of hematological changes in patients with rheumatoid arthritis treated with different Janus kinase inhibitors: a real-world study.","authors":"Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong","doi":"10.4078/jrd.2025.0081","DOIUrl":"10.4078/jrd.2025.0081","url":null,"abstract":"Objective: Janus kinase (JAK) inhibitors are widely used to treat rheumatoid arthritis (RA); however, comparative analyses regarding their adverse events remain limited. This study aimed to compare the effects of different JAK inhibitors (tofacitinib, baricitinib, and upadacitinib) on hematological parameters in patients with RA in a real-world setting.Methods: This retrospective analysis included 552 patients with RA treated with JAK inhibitors between August 2015 and February 2024. Hematological parameters, including absolute neutrophil count (ANC) and platelet count, were assessed at baseline and after 6 months of treatment. Statistical analysis was performed to evaluate changes over time, and logistic regression analysis identified factors associated with hematologic alterations.Results: The 552 patients were divided into three groups tofacitinib (n=264), baricitinib (n=143), and upadacitinib (n=145). No significant differences in baseline hematological parameters were observed across the groups. After 6 months, ANC decreased in all groups without significant differences among them (p=0.465). Patients receiving baricitinib had significantly higher platelet counts than those receiving tofacitinib (Pillai's trace value of 0.063, p<0.001) or upadacitinib (Pillai's trace value of 0.029, p<0.001). Multivariate analysis revealed that baricitinib was significantly associated with increased platelet counts (odds ratio, 2.009; 95% confidence interval, 1.212~3.331; p=0.007).Conclusion: Although all three JAK inhibitors reduced ANC, baricitinib was associated with a substantial increase in platelet counts. These findings highlight the differences in adverse effect profiles among JAK inhibitors, emphasizing the importance of tailored monitoring in RA management.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 2","pages":"86-94"},"PeriodicalIF":3.8,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of literature: posterior reversible encephalopathy syndrome in systemic lupus erythematosus. 文献综述：系统性红斑狼疮后可逆性脑病综合征。

IF 3

Journal of Rheumatic Diseases Pub Date : 2026-01-01 Epub Date: 2025-04-21 DOI: 10.4078/jrd.2025.0010

Farah Jaafar Mahdi

{"title":"Review of literature: posterior reversible encephalopathy syndrome in systemic lupus erythematosus.","authors":"Farah Jaafar Mahdi","doi":"10.4078/jrd.2025.0010","DOIUrl":"10.4078/jrd.2025.0010","url":null,"abstract":"Posterior reversible encephalopathy syndrome (PRES) is a neuroradiological disorder primarily affecting the posterior circulation of the brain. It manifests with a spectrum of symptoms, typically accompanied by hypertension, headache, seizures, and blurred vision. The etiology of PRES remains uncertain, but it is believed to be associated with vasogenic edema. The underlying conditions can range from sepsis to drug-induced states, autoimmune diseases, systemic lupus erythematosus (SLE), which is the most prevalent connective tissue disease associated with PRES. SLE is a multisystemic disorder that impacts various organs in the body, with musculoskeletal and skin systems being the most affected. The morbidity and mortality associated with SLE stem from its potential involvement of life-threatening organs, including the central nervous system, kidneys, and respiratory system. This article will focus on the neurological impact of PRES, including its manifestations. The association between PRES and SLE will be discussed in detail, accompanied by a literature review that explores the variability of presentation, reversibility, and prognosis.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 1","pages":"3-6"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12706435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of cardiovascular disease associated with use of tumor necrosis factor inhibitors in ankylosing spondylitis. 强直性脊柱炎患者使用肿瘤坏死因子抑制剂相关的心血管疾病风险

IF 3

Journal of Rheumatic Diseases Pub Date : 2026-01-01 Epub Date: 2025-08-26 DOI: 10.4078/jrd.2025.0070

Ji-Won Kim, Jun Sik Yoon, Sojeong Park, Hasung Kim, Bo Young Kim, Hwajeong Lee, Sung-Hoon Park, Seong-Kyu Kim, Jung-Yoon Choe

{"title":"Risk of cardiovascular disease associated with use of tumor necrosis factor inhibitors in ankylosing spondylitis.","authors":"Ji-Won Kim, Jun Sik Yoon, Sojeong Park, Hasung Kim, Bo Young Kim, Hwajeong Lee, Sung-Hoon Park, Seong-Kyu Kim, Jung-Yoon Choe","doi":"10.4078/jrd.2025.0070","DOIUrl":"10.4078/jrd.2025.0070","url":null,"abstract":"Objective: To examine the risk of cardiovascular disease (CVD) associated with use of tumor necrosis factor inhibitors (TNFi) in patients with ankylosing spondylitis (AS).Methods: This study used data from the Korean National Health Insurance database. Patients aged ≥18 years who were newly diagnosed with AS between 2010 and 2018 and did not suffer prior CVD were included. The primary outcome was a composite endpoint of myocardial infarction (MI) or stroke. The secondary outcomes were specific endpoints of MI, stroke, or congestive heart failure. TNFi use was evaluated as a time-dependent variable. Cox proportional hazard regression was used to examine the association between TNFi use and risk of incident CVD.Results: Of 19,775 patients (mean age, 36.1 years; 75% male), 5,978 (30.2%) were exposed to TNFi treatment during the study period. During a follow-up of 4.8 (interquartile range, 2.9~7.2) years, 522 events of MI or stroke occurred. TNFi use was associated with a lower risk of MI or stroke than no TNFi use after adjusting for traditional CV risk factors and medications (adjusted hazard ratio [aHR], 0.72; 95% confidence interval [CI], 0.55~0.94). The lower risk of MI or stroke associated with TNFi use was consistently observed across subgroups. Risk of congestive heart failure did not differ between users and non-users of TNFi (aHR, 0.94; 95% CI, 0.75~1.18).Conclusion: In a real-world AS cohort, TNFi treatment was associated with a reduced risk of atherosclerotic CVD. However, TNFi use was not associated with risk of congestive heart failure.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 1","pages":"46-54"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12706437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision and contextualization in claims-based disease activity assessment for systemic lupus erythematosus in Korean populations. 韩国人群系统性红斑狼疮疾病活动性评估的准确性和情境化。

IF 3

Journal of Rheumatic Diseases Pub Date : 2026-01-01 Epub Date: 2025-10-28 DOI: 10.4078/jrd.2025.0148

Seung Cheol Shim

引用次数: 0

Elevated circulating interleukin-17 levels in systemic sclerosis: a meta-analysis. 系统性硬化症患者循环白细胞介素-17水平升高：荟萃分析。

IF 3

Journal of Rheumatic Diseases Pub Date : 2026-01-01 Epub Date: 2025-09-01 DOI: 10.4078/jrd.2025.0056

Young Ho Lee, Gwan Gyu Song

{"title":"Elevated circulating interleukin-17 levels in systemic sclerosis: a meta-analysis.","authors":"Young Ho Lee, Gwan Gyu Song","doi":"10.4078/jrd.2025.0056","DOIUrl":"10.4078/jrd.2025.0056","url":null,"abstract":"Objective: The aim of this meta-analysis was to evaluate the association between circulating interleukin-17 (IL-17) levels and systemic sclerosis (SSc).Methods: We conducted a comprehensive systematic search in MEDLINE, Embase, and Web of Science for relevant studies. The meta-analysis compared serum/plasma IL-17, IL-17A, IL-17B, IL-17E, and IL-17F levels in SSc patients with those in control subjects, incorporating subgroup analyses based on ethnicity and disease subtype.Results: This analysis included 16 studies, comprising 1,229 patients diagnosed with SSc and 839 control participants. The meta-analysis did not identify a significant difference in circulating IL-17 levels between SSc patients and controls in overall group (standardized mean difference [SMD]=0.260; 95% confidence interval [CI]=-1.805 to 2.336; p=0.825). However, recent studies supported this finding, demonstrating a stronger association (SMD=2.040; 95% CI=1.049 to 3.030; p<0.001). IL-17A levels were significantly higher in SSc patients (SMD=2.046; 95% CI=0.724 to 3.369; p=0.002), along with notable increases in IL-17B (SMD=0.764; 95% CI=0.230 to 1.298; p=0.005), IL-17E (SMD=0.672; 95% CI=0.282 to 1.062; p=0.001), and IL-17F (SMD=0.402; 95% CI=0.019 to 0.784; p=0.039). However, no significant difference in IL-17A levels was observed between diffuse and limited SSc groups.Conclusion: IL-17A, IL-17B, IL-17E, and IL-17F were significantly elevated in SSc, with IL-17A demonstrating the most pronounced association. These findings suggest that specific IL-17 subtypes, particularly IL-17A, play a role in SSc pathogenesis.","PeriodicalId":56161,"journal":{"name":"Journal of Rheumatic Diseases","volume":"33 1","pages":"37-45"},"PeriodicalIF":3.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12706430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0